110 related articles for article (PubMed ID: 10686798)
1. [Role of positron emission tomography is the evaluation of digestive tract tumors].
Hustinx R; Paulus P; Daenen F; Detroz B; Honoré P; Jacquet N; Rigo P
Rev Med Liege; 1999 Dec; 54(12):925-30. PubMed ID: 10686798
[TBL] [Abstract][Full Text] [Related]
2. PET imaging in assessing gastrointestinal tumors.
Hustinx R
Radiol Clin North Am; 2004 Nov; 42(6):1123-39, ix. PubMed ID: 15488562
[TBL] [Abstract][Full Text] [Related]
3. Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms.
Gupta N; Bradfield H
Semin Nucl Med; 1996 Jan; 26(1):65-73. PubMed ID: 8623053
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
[TBL] [Abstract][Full Text] [Related]
5. [Positron emission tomography and gastrointestinal oncology].
Ducreux M; Taieb J; Boige V; Lasser P; Elias D; Lumbroso J
Gastroenterol Clin Biol; 2003 May; 27(5 Suppl):B71-8. PubMed ID: 12843940
[No Abstract] [Full Text] [Related]
6. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
Zimny M; Schumpelick V
Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
[TBL] [Abstract][Full Text] [Related]
7. [Role of 18F-FDG positron emission tomography in surgical evaluation].
Franzius C; Sciuk J; Schober O
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():261-9. PubMed ID: 9931622
[TBL] [Abstract][Full Text] [Related]
8. [Positron emission tomography (PET) in gastro-intestinal cancer].
Wartski M
Presse Med; 2016 Sep; 45(9):734-41. PubMed ID: 27542763
[TBL] [Abstract][Full Text] [Related]
9. [Recommendations for clinical practice: use of TEP-FDG in cancer of the esophagus, stomach, colon and rectum, anal canal, large intestine, pancreas and bile ducts, liver and endocrine tumors (digestive system)].
Bourguet P; Planchamp F; Monteil J; Metges JP; Mitry E; Tubiana-Mathieu N
Bull Cancer; 2007 Feb; 94(2):212-8. PubMed ID: 17338096
[No Abstract] [Full Text] [Related]
10. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in digestive system neoplasms].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S56-66. PubMed ID: 12739337
[No Abstract] [Full Text] [Related]
11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic ultrasonography.
Bhutani MS
Endoscopy; 2002 Nov; 34(11):888-95. PubMed ID: 12430073
[No Abstract] [Full Text] [Related]
13. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract.
Annovazzi A; Peeters M; Maenhout A; Signore A; Dierckx R; Van De Wiele C
Gastroenterology; 2003 Oct; 125(4):1235-45. PubMed ID: 14517805
[No Abstract] [Full Text] [Related]
14. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
15. The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease.
Rajput A; Stellato TA; Faulhaber PF; Vesselle HJ; Miraldi F
Surgery; 1998 Oct; 124(4):793-7; discussion 797-8. PubMed ID: 9781003
[TBL] [Abstract][Full Text] [Related]
16. Cross-sectional imaging and the role of positron emission tomography in pancreatic cancer evaluation.
Raman SP; Chen Y; Fishman EK
Semin Oncol; 2015 Feb; 42(1):40-58. PubMed ID: 25726051
[TBL] [Abstract][Full Text] [Related]
17. Advances in positron emission tomography imaging for the GI tract.
Pham KH; Ramaswamy MR; Hawkins RA
Gastrointest Endosc; 2002 Jun; 55(7 Suppl):S53-63. PubMed ID: 12024124
[No Abstract] [Full Text] [Related]
18. [Can the extent of pancreatic tumors be evaluated reliably enough by positron emission tomography (PET)].
Sendler A; Avril N; Roder JD; Schwaiger M; Siewert JR
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1485-7. PubMed ID: 9931919
[TBL] [Abstract][Full Text] [Related]
19. 18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma.
Matsumoto I; Shirakawa S; Shinzeki M; Asari S; Goto T; Ajiki T; Fukumoto T; Kitajima K; Ku Y
Clin Gastroenterol Hepatol; 2013 Jun; 11(6):712-8. PubMed ID: 23353642
[TBL] [Abstract][Full Text] [Related]
20. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
